Chemomab Therapeutics Ltd. — Form SCHEDULE 13D
Filed November 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 78/100
What the filing says
Scipher Medicine Corporation entered into a Convertible Note Purchase and Investment Obligation Agreement (March 5, 2026) with major VCs including Khosla Ventures, Northpond Capital, Blue Owl Healthcare, and others to raise $5.87M+ in convertible notes and commit to $23.49M+ in equity investment upon closing of a Strategic Transaction (reverse merger with Chemomab Therapeutics Ltd., now called Snowdrift Parent). The agreement was amended three times (June 23, July 17, October 29, 2026) extending deadlines to March 31, 2027, authorizing additional July and October 2026 note closings, and allowing investors to satisfy obligations via Chemomab's ATM program. On November 3, 2026, Chemomab consented to Scipher issuing up to $1.1M additional bridge notes to fund Chemomab's pre-closing financing needs.
Why this rating
Major financing and M&A structuring relative to Chemomab's $37.9M market cap. Combined convertible debt + PIPE commitment (~$29M) and multiple amendments extending timelines signal deal complexity but no completed reverse merger. Significant for trajectory but timing/execution risk remains.
Price action (we called it neutral)
at our read · unknown $1.36 | +10 min · unknown $1.42 ▲ 4.57% | +30 min · unknown $1.40 ▲ 3.09% | +1 hr · unknown $1.38 ▲ 1.25% | +4 hrs · unknown $1.27 ▼ 6.11% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.